Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

  • 1, 2,
  • 3,
  • 1,
  • 2,
  • 1,
  • 1,
  • 4,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 5,
  • 6,
  • 7,
  • 8,
  • 1Email author,
  • 2Email author and
  • 1Email author
Journal of Hematology & Oncology201811:56

https://doi.org/10.1186/s13045-018-0599-z

  • Received: 4 April 2018
  • Accepted: 6 April 2018
  • Published:

The original article was published in Journal of Hematology & Oncology 2018 11:12

The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.
Fig. 5
Fig. 5

FOXO3a exerts an important mediator in miR-182-5p induced Wnt signaling activation. a Western blot analysis of Wnt signaling pathway related proteins following miR-182-5p overexpression and knockdown. b IHC staining of FOXO3a and β-catenin in orthotopic tumor tissues of negative control and overexpression of miR-182-5p. c Western blot analysis of c-Myc in miR-NC cells treated with different concentration of XAV939 (0, 1, 5, 10, 100, and 200 μM). d Transwell assay of HCC cells that transfected with miR-NC, overexpression of miR-182-5p and miR-182-5p overexpression cells that further treated with 10 μM XAV939. e Western blot analysis of Wnt signaling pathway-related proteins in miR-NC cells, overexpression of miR-182-5p cells and miR-182-5p overexpression cells further overexpress FOXO3a

As such, the correct version of Fig. 5a with the correct representation of the Western blots of SGK can be seen ahead.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China
(2)
Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China
(3)
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Haidian District, Beijing, 100142, China
(4)
Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China
(5)
Department of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China
(6)
Department of Organ Transplantation, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China
(7)
Department of Liver Surgery, Fudan University Shanghai Cancer Center, Cancer Hospital, Shanghai, 200032, China
(8)
Department of Breast Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China

Reference

  1. Cao M-Q, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11:12.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement